根据中金公司和演讲嘉宾书面许可任何机构和个人不得以任何形式将会议内容和相关信息独白公布转发转载传播复制编辑修改等如有上述违法行为中金公司保留追究相关方法律责任的权利This meeting is a closed-door meeting of China International Capital Corporation Limited, CICCand only invited guests are allowed to attend 各位投资者各位分析师大家早上好 欢迎参加要民生业务更新电话会我是中进的张进在线的还有我的同事余波和吴瓦华大家也看到昨天晚上公司公告了爱尔兰疫苗工厂与摩沙当达成了一个协议今天早上我们非常荣幸邀请到公司的管理团队为大家解读这一次的一个交易那么除去本次电话会的有公司 做这个项目最主要的目的所以我们是希望一个是我们聚焦聚焦我们的core business另外一个是说我们把钱拿回来我们可以投资到性价比更高的业务投资到回报更高的业务还有一个就是如果我们钱足够了那我们还可以回收股票所以这是项目的初衷 但是我们也非常感谢莫沙东这么几年后跟我们一起合作我们和莫沙东通过这个疫苗项目的合作是更紧 ...

SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced an agreement with Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases.Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager ...

Leading Green CRDMO Driven by Innovation for a Healthier Future Offering End-to-end Green Biologics Solutions for the Entire IndustrySHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been included in the "20 Case Examples for 20 Years: Private Sector's Sustainable Development in China" report initiated by the United Nations Global Compact. The company has been in ...

Multiple successful 16,000L PPQ runs highlight that disposable manufacturing can achieve similar performance as traditional stainless reactors GMP Authorizations by HPRA demonstrate that new global sites have built strong world-class regulatory and quality system DUNDALK, Ireland, Dec. 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced major accomplishments at its cutting-edge greenfield site ...

LEVERKUSEN, Germany, Nov. 13, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it will enhance its drug product (DP) capabilities at the company's facility in Leverkusen, Germany, with a new sterile filling line for prefilled syringes (PFS) using isolator technology.Construction of the new line will optimize the design of the Leverkusen facility's manufacturing layout to be more efficient for m ...

SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expression system platform. The platform, specialized in non-antibiotic cell line development, employs zinc finger nucleases (ZFN) technology for targeted knockout of the endogenous GS gene in CHO cells. Based on the WuXia™ ...

HONG KONG, Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has received a Platinum Award from The Asset ESG (Environmental, Social and Governance) Corporate Awards for the fourth year in a row. The prestigious honor recognizes the company's unwavering commitment to sustainable practices as well as its effective approaches to driving innovation and efficiency through green tech ...

HONG KONG, Sept. 23, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has been included in the Hang Seng ESG 50 Index, making it the only pharmaceutical company selected this year. The Index became effective September 9, following the Hang Seng Indexes review results announcement in August. Launched in 2020, the Hang Seng ESG 50 Index aims to capture the performance of Top 50 ESG leader ...

By leveraging its ultra-intensified fed-batch platform, WuXiUI™, WuXi Biologics has completed its first scale-up to 2,000L drug substance (DS) GMP manufacturing, achieving a 4-fold productivity improvement compared to the traditional fed-batch process The competitive performance achieved through the utilization of both WuXiUI™ and the proprietary platform cell culture media MagniCHO™ led to significant reduction in overall DS manufacturing COGS The consistent performance of WuXiUI™ – from small scales to 2, ...

WuXi Biologics (Cayman) Inc. (OTCPK:WXXWY) Q2 2024 Earnings Conference Call August 22, 2024 8:30 AM ET Company Participants Lina Fan - Senior Vice President, Head of Investor Relations Chris Chen - Chief Executive Officer Ming Tu - Chief Financial Officer, Executive Vice President Ziyi Chen - China Healthcare Analyst, Goldman Sachs Conference Call Participants Chen Chen - UBS Samuel Isaly - Exome Asset Management Jingyi Li - Harding Loevner Ziyi Chen Great. Good morning and good evening, global investors. T ...